Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 254

Sort by

Sort Order Select

Journal Articles

Systemic mastocytosis with an associated t(8;21)(q22;q22) acute myeloid leukemia

Jordan Wimmer, Remy Hurstel

Blood (2021) 137 (18): 2564.

https://doi.org/10.1182/blood.2021010957

Published: 2021

Journal Articles

Nintedanib targets KIT D816V neoplastic cells derived from induced pluripotent stem cells of systemic mastocytosis

Blood (2021) 137 (15): 2070–2084.

https://doi.org/10.1182/blood.2019004509

Published: 2021

Includes: Supplemental data

Journal Articles

New developments in diagnosis, prognostication, and treatment of advanced systemic mastocytosis

Andreas Reiter, Tracy I. George, Jason Gotlib

Blood (2020) 135 (16): 1365–1376.

https://doi.org/10.1182/blood.2019000932

Published: 2020

Journal Articles

BCL-2 Is Expressed in Advanced Mastocytosis and Midaustorin Induces Venetoclax Sensitivity of Mast Leukemia Cell Lines

Danielle Canioni, MD, Josquin Moraly, MD, Ludovic Lhermitte, MD PhD, Laura Polivka, MD, Mélanie Féroul, Julien Rossignol, MD PhD, Laurent Frenzel, MD PhD, Michel Arock, pharmD, PhD, Patrice Dubreuil, PhD, Leila maouche-Chretien, PhD, Olivier Hermine, MD PhD

Blood (2019) 134 (Supplement_1): 1683.

https://doi.org/10.1182/blood-2019-131256

Published: 2019

Journal Articles

Bone Marrow Mastocytosis Is Independently Associated with Inferior Survival in Chronic Myelomonocytic Leukemia

Andrew T Kuykendall, MD, Anthony Hunter, MD, Ling Zhang, MD, Eric Padron, MD, Chetasi Talati, MD, Rami S. Komrokji, MD

Blood (2019) 134 (Supplement_1): 2956.

https://doi.org/10.1182/blood-2019-130661

Published: 2019

Journal Articles

UK Single Institution Experience of Mastocytosis: Guy's and St Thomas' NHS Foundation Trust

Clare Oni, MD, Mufaddal Moonim, MD, Joana Desterro, MD, Clive Grattan, MD, Natalia Curto-Garcia, MD, Claire Woodley, Monika Ciesielska, Deimante Drasutyte, Yvonne Francis, Jennifer O'Sullivan, MD, Thompson Olaoni, Anna Green, MD, Miki Yurina, MD, Mark Ong, MD, Nick C.P. Cross, Professor, Donal P. McLornan, MB, BCh (Hons), MRCP, PhD FRCPath, Deepti Radia

Blood (2019) 134 (Supplement_1): 2960.

https://doi.org/10.1182/blood-2019-130477

Published: 2019

Journal Articles

Pioneer: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Avapritinib in Patients with Indolent or Smoldering Systemic Mastocytosis with Symptoms Inadequately Controlled with Standard Therapy

Blood (2019) 134 (Supplement_1): 2950.

https://doi.org/10.1182/blood-2019-126035

Published: 2019

Journal Articles

Real-World Utilization of Midostaurin Among Patients with Systemic Mastocytosis (SM)

Ajeet Gajra, MD FACP, Andrew J Klink, PhD MPH, Dhruv Chopra, MS, Bruce Feinberg, DO

Blood (2019) 134 (Supplement_1): 5378.

https://doi.org/10.1182/blood-2019-131028

Published: 2019

Journal Articles

Comparison of RNA-Based Versus DNA-Based Quantitative KIT D816V Mutation Analysis Reveals Significant Disparity in Patients with Advanced Systemic Mastocytosis

Mohamad Jawhar, Nicole Naumann, Johannes Lübke, Juliana Schwaab, Oliver Hofmann, Thomas Kielsgaard Kristensen, Karl Sotlar, Verena Haselmann, Sven Schneider, Georgia Metzgeroth, Henning D. Popp, Alice Fabarius, PhD, Peter Bugert, Wolf-Karsten Hofmann, MD PhD, Andreas Reiter

Blood (2019) 134 (Supplement_1): 2955.

https://doi.org/10.1182/blood-2019-128811

Published: 2019

Journal Articles

An Increased Bone Mineral Density As an Adverse Prognostic Factor in Patients with Systemic Mastocytosis

Mohamad Jawhar, Juliana Schwaab, Nicole Naumann, Georgia Metzgeroth, Alice Fabarius, PhD, Stefan O Schoenberg, Wolf-Karsten Hofmann, MD PhD, Philipp Riffel, Andreas Reiter

Blood (2019) 134 (Supplement_1): 4185.

https://doi.org/10.1182/blood-2019-129798

Published: 2019

Journal Articles

In Systemic Masocytosis, Midostaurin Targets Both Kit and Aurora Kinase a Reverting H3K36Me3 Deficiency and Synergizes with Second-Generation Tyrosine Kinase Inhibitors

Blood (2019) 134 (Supplement_1): 4204.

https://doi.org/10.1182/blood-2019-126538

Published: 2019

Journal Articles

Clinical Utility of a Multi-Gene Next-Generation Sequencing Myeloid Panel in an Academic Hematology Practice

Pedro G Vianna, BSc,MD, Richard D. Press, MD PhD, Henning Stehr, PhD, Fei Yang, MD, Linda Gojenola, James L Zehnder, Jason Gotlib, MD MS

Blood (2019) 134 (Supplement_1): 1408.

https://doi.org/10.1182/blood-2019-124445

Published: 2019

Journal Articles

Loss of Dnmt3a Dysregulates Hematopoietic Homeostasis and Myeloid Skewing Via the PI3Kinase Pathway: PI3Kα/β Inhibition Corrects Extramedullary Hematopoiesis and Myeloid Skewing Due to Loss of Dnmt3a

Lakshmi Reddy Palam, PhD, Baskar Ramdas, PhD, Katelyn Pickerell, Reuben Kapur, PhD

Blood (2019) 134 (Supplement_1): 723.

https://doi.org/10.1182/blood-2019-131036

Published: 2019

Journal Articles

Systemic mastocytosis with an associated hematological neoplasm masquerading as overt primary myelofibrosis

Rebecca Z. Xu, Zhaodong Xu

Blood (2018) 132 (24): 2613.

https://doi.org/10.1182/blood-2018-09-875914

Published: 2018

Journal Articles

Cytogenetic Abnormalities in Systemic Mastocytosis: Who Subcategory-Specific Incidence and Prognostic Impact Among 348 Informative Cases

Sahrish Shah, MD, Animesh Pardanani, MBBS, PhD, Yoseph Elala, MD, Terra L. Lasho, PhD, Mrinal M. Patnaik, MD MBBS, Kaaren K. Reichard, MD, Curtis A. Hanson, MD, Rhett P. Ketterling, Ayalew Tefferi, MD

Blood (2018) 132 (Supplement 1): 3050.

https://doi.org/10.1182/blood-2018-99-112628

Published: 2018

Journal Articles

Temporal and Spatially Regulated Oncogenic KIT Expression and Loss of Dnmt3a Cooperate to Drive MPN Development: Role of PI3Kinase in Dnmt3a Loss Induced Hyperproliferation in Myeloid Cells

Lakshmi Reddy Palam, PhD, Baskar Ramdas, PhD, Sridhar reddy Srivatsan, MS, Sarath Chandra Janga, PhD, Axel Roers, PhD, Alexander Gerbaulet, Reuben Kapur, PhD

Blood (2018) 132 (Supplement 1): 3055.

https://doi.org/10.1182/blood-2018-99-118721

Published: 2018

Journal Articles

Molecular Quantification of Tissue Mast Cell Burden in Systemic Mastocytosis: A New Approach for Diagnostics and Prognostication

Greiner Georg, MD PhD, Michael Gurbisz, MSc, Franz Ratzinger, MD, Nadine Witzeneder, MSc, Svenja-Verena Class, Ingrid Simonitsch-Klupp, MD, Harald Esterbauer, MD PhD, Matthias Mayerhofer, MD, Wolfgang R. Sperr, Leonhard Muellauer, MD PhD, Peter Valent, Gregor Hoermann

Blood (2018) 132 (Supplement 1): 3043.

https://doi.org/10.1182/blood-2018-99-116492

Published: 2018

Journal Articles

A New Prognostic Score for Advanced Systemic Mastocytosis Based on Clinical and Genetic Characteristics of 210 Consecutive Patients

Mohamad Jawhar, Juliana Schwaab, Nicole Naumann, Georgia Metzgeroth, MD, Hans-Peter Horny, Karl Sotlar, Manja Meggendorfer, PhD, Torsten Haferlach, MD, Nicholas C.P. Cross, Alice Fabarius, Wolf-Karsten Hofmann, Peter Valent, Andreas Reiter, MD

Blood (2018) 132 (Supplement 1): 349.

https://doi.org/10.1182/blood-2018-99-115804

Published: 2018

Journal Articles

Immunophenotypic Patterns of Bone Marrow Eosinopoiesis in Patients with Hypereosinophillic Syndrome and Systemic Mastocytosis

Christopher Trindade, MD, Xiaoping Sun, PhD, Dragan Maric, PhD, Chunjie Jiang, Christopher S. Hourigan, DPhil FACP FRCP, Dean D. Metcalfe, MD, Amy Klion, MD, Irina Maric, MD MSci

Blood (2018) 132 (Supplement 1): 4294.

https://doi.org/10.1182/blood-2018-99-118797

Published: 2018

Journal Articles

Systemic Mastocytosis: Management and Outcome. Data Analysis from the Greek Registry

Ioannis Tsonis, MD, Nikolaos Kanellias, MD, Vasileios Lazaris, Panayiotis Panayiotidis, MD PhD, Damianos Sotiropoulos, MD, Theodoros Vassilakopoulos, MD, Zoi Arapidou, MD, Evangelos Eleutherakis-Papaiakovou, MD, Dimitrios Boutsis, Athanasios Galanopoulos, MD PhD, Ioannis Kotsianidis, MD PhD, Marie-Christine Kyrtsonis, MD PhD, Theoni Leonidopoulou, MD, Gerasimos Pangalis, MD, Maria Papaioannou, Sophia Polychronopoulou, MD PhD, Charalampos Pontikoglou, MD PhD, Elias Poulakidas, Christos Poziopoulos, MD, Panagiotis Repousis, MD, Maria Topalidou, Kalliopi Vallianatou, Elina Vervessou, MD, Nora-Athina Viniou, Maria Angelopoulou, MD, Ioannis Baltadakis, MD, Maria Dimou, MD PhD, Eleni Gavriilaki, MD, Theodoros Iliakis, MD, Argiris Symeonidis, MD PhD, Sossana Delibasi, MD, Maria Papathanassiou, Theodoros Marinakis, Panagiotis Tsirigotis, MD, Nikolaos Charchalakis, PhD, Evangelos Terpos, MD PhD, Maria Pagoni

Blood (2018) 132 (Supplement 1): 5463.

https://doi.org/10.1182/blood-2018-99-116693

Published: 2018

NARROW

Systemic mastocytosis with an associated t(8;21)(q22;q22) acute myeloid leukemia

Nintedanib targets KIT D816V neoplastic cells derived from induced pluripotent stem cells of systemic mastocytosis

New developments in diagnosis, prognostication, and treatment of advanced systemic mastocytosis

BCL-2 Is Expressed in Advanced Mastocytosis and Midaustorin Induces Venetoclax Sensitivity of Mast Leukemia Cell Lines

Bone Marrow Mastocytosis Is Independently Associated with Inferior Survival in Chronic Myelomonocytic Leukemia

UK Single Institution Experience of Mastocytosis: Guy's and St Thomas' NHS Foundation Trust

Pioneer: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Avapritinib in Patients with Indolent or Smoldering Systemic Mastocytosis with Symptoms Inadequately Controlled with Standard Therapy

Real-World Utilization of Midostaurin Among Patients with Systemic Mastocytosis (SM)

Comparison of RNA-Based Versus DNA-Based Quantitative KIT D816V Mutation Analysis Reveals Significant Disparity in Patients with Advanced Systemic Mastocytosis

An Increased Bone Mineral Density As an Adverse Prognostic Factor in Patients with Systemic Mastocytosis

In Systemic Masocytosis, Midostaurin Targets Both Kit and Aurora Kinase a Reverting H3K36Me3 Deficiency and Synergizes with Second-Generation Tyrosine Kinase Inhibitors

Clinical Utility of a Multi-Gene Next-Generation Sequencing Myeloid Panel in an Academic Hematology Practice

Loss of Dnmt3a Dysregulates Hematopoietic Homeostasis and Myeloid Skewing Via the PI3Kinase Pathway: PI3Kα/β Inhibition Corrects Extramedullary Hematopoiesis and Myeloid Skewing Due to Loss of Dnmt3a

Systemic mastocytosis with an associated hematological neoplasm masquerading as overt primary myelofibrosis

Cytogenetic Abnormalities in Systemic Mastocytosis: Who Subcategory-Specific Incidence and Prognostic Impact Among 348 Informative Cases

Temporal and Spatially Regulated Oncogenic KIT Expression and Loss of Dnmt3a Cooperate to Drive MPN Development: Role of PI3Kinase in Dnmt3a Loss Induced Hyperproliferation in Myeloid Cells

Molecular Quantification of Tissue Mast Cell Burden in Systemic Mastocytosis: A New Approach for Diagnostics and Prognostication

A New Prognostic Score for Advanced Systemic Mastocytosis Based on Clinical and Genetic Characteristics of 210 Consecutive Patients

Immunophenotypic Patterns of Bone Marrow Eosinopoiesis in Patients with Hypereosinophillic Syndrome and Systemic Mastocytosis

Systemic Mastocytosis: Management and Outcome. Data Analysis from the Greek Registry

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only